Heterogeneous Cardiovascular Effects of SGLT2 Inhibitors in Type 2 Diabetes: A Causal Forest and Target Trial Emulation Study

By afschroeder • September 2, 2025

Mori Y, Komura T, Adomi M, Yagi R, Fukuma S, Kawakami K, Kondo N, Tsugawa Y, Yabe D, Yanagita M, Inoue K. Heterogeneous Cardiovascular Effects of SGLT2 Inhibitors in Type 2 Diabetes: A Causal Forest and Target Trial Emulation Study. Eur J Prev Cardiol. 2025 Sep 1:zwaf539. doi: 10.1093/eurjpc/zwaf539. Epub ahead of print. PMID: 40889271.

Tags: General Internal Medicine, Publications

Related Posts

Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis

Kishan AU, Sun Y, Parker CC, Sargos P, Sydes MR, Chabaud S, Brihoum M, Kalbasi TR, Steinberg ML, Valle LF, Taparra K, Shoag JE, Garcia[...]

Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes: a prospective cohort study

Nguyen XT, Li Y, Czernichow S, Rassy N, Houghton SC, Lu B, Ho YL, Charest BR, Wang DD, Gagnon DR, Gaziano JM, Willett WC, Wilson[...]

Discontinuation of statins by patient and physician sex: An observational study

Watanabe A, Miyamoto Y, Ueyama HA, Gotanda H, Slipczuk L, Inoue K, Secemsky E, Laham R, Bhatt DL, Tsugawa Y, Kuno T. Discontinuation of statins[...]